Sunday Long Reads: Planet Hollywood, Autocratic Democracy, Nuclear is another word for gas, Ruth Madoff, Terrible Canadian schools
I think Optibiotix (OPTI) shares are very cheap as are those of Skinbiotherapeutics (SBTX) and am a loyal shareholder in both expecting to treble my money from here. Nor do I begrudge Optibiotix selling a few shares in Skinbiotherapeutics as it announced it had today as I imagine that will more than pay for a Nasdaq listing which may drive a re-rate. But I suggest that, in light of today's events, a document signed by Steve O’Hara and Nomad and broker Cenkos is a worthless piece of toilet paper and both have legged over and deceived investors in Skinbiotherapeutics. Let me explain.
OptiBiotix Health (OPTI) has announced a “Commercial strategy update” which shows strong progress in its strategy to initially build sales and brand presence and then move up the value chain by selling more product than ingredients and commercialising further compounds. We’ve also had a catch up chat with CEO Steve O'Hara. This should be THE YEAR when profits come close to or exceed £1 million.
As a loyal shareholder I see nothing to shock me and a good bit to please. Specifically:
OptiBiotix Health (OPTI) has announced a trading update, emphasising “another year of progress… probiotic and functional fibre divisions achieving profitability”. The shares have though currently responded lower to 55.5p, so what’s the current situation here? We’ve spoken to Chief Executive Steve O'Hara and we believe that Mr Market has got this one wrong.
I am a massive shareholder in Optibiotix (OPTI) and believe that I will do very well from my investment, where my average in price is c9p. The shares are now 61.5p mid and I think they will easily double from here within 18 months if not far sooner. But there can be no double standards here in the way that I cover companies, just because I own shares in them. I think the company has made a material accounting error which is also an own goal! Here's why:
Optibiotix (OPTI) has announced that Non Executive Director (NED) Peter Wennstrom – of whom we’d never heard – is to step down to be replaced by Christopher Brinsmead CBE, subject to the completion of regulatory due diligence being carried out by the Company's Nomad. For a £50 million odd capitalised company, Brinsmead is a real BSD to pick up.
OptiBiotix Health (OPTI) has emphasised “another step in building brand and product presence in the large North American market" as it announced its latest deal. Yes it is a step but frustratingly one revealed on a release using the Adam Reynolds keyboard. The one with no numbers on it.
OptiBiotix Health (OPTI) “announces the launch of meal replacement shakes and bars containing OptiBiotix's OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, Chemist Warehouse and on OptiPharm Pty Ltd's online store in Australia and New Zealand”...
OptiBiotix Health (OPTI) is “pleased to have signed an agreement with UITC to distribute CholBiomeX3 in Singapore”...
I have a small holding in AIM-listed Optibiotix (OPTI) – perhaps Tom Winnifrith’s favourite stock. It has been a wild ride, with the shares having headed above £1 a pop but the stock has certainly been in the doldrums recently, having tested 50p over the summer and has now perked up to just 63p. Yet we are getting an extended flurry of contracts and deals which should transform this business, which as far as I can see has little issue over cash whilst we await the mega-profits promised. What gives?...
OptiBiotix Health (OPTI) is “pleased to see that Seed has achieved FDA authorisation for an IND in a product containing OptiBiotix's Lactobacillus plantarum LPLDL®”. So, what does this mean?...
OptiBiotix (OPTI) has announced that it is “pleased to have signed an agreement with UITC to distribute our award-winning medical device in Singapore”...
OptiBiotix Health (OPTI) is “pleased to present… results for the six month period ended 30 June 2020” and we have had a chat with CEO Steve O'Hara...
OptiBiotix Health (OPTI) is “pleased to announce… an exclusive distribution agreement with Ayalla Marketing for the distribution of its cholesterol reducing probiotic, LPLDL®, as an ingredient and as four finished products (CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH) within the CholBiome® portfolio for Brazil”...
OptiBiotix Health (OPTI) is “pleased to announce that it has has entered into an agreement with a US company for the purpose of large scale manufacture and commercialisation of a number of SweetBiotix® products”...
OptiBiotix Health (OPTI) has recently been “pleased to announce the extension of terms for CTC. This agreement recognises CTC's success in building sales of SlimBiome® and extends terms to enhance further sales growth, supported by minimum sales targets. This is a first commercial step in bringing our new functional ingredient WellBiome® to global markets and building brand awareness” and “pleased to announce… a second commercial step in bringing OptiBiotix's new functional ingredient WellBiome® to global markets and building brand awareness”...
More news from OptiBiotix Health (OPTI) and we’re also asked to clarify re. previous statements by the company...
Yesterday I explained how Optibiotix (OPTI) has sold 4.5 million shares in Skinbiotherapeutics (SBTX) on Friday, a trade yet to be announced but where the buyer is clearly already selling. But this scandal is, I believe far, far bigger and should be enough to see SP Angel cold shouldered by the AIM Community.
Currently compounds to tackle obesity, high cholesterol and diabetes developer, OptiBiotix Health (OPTI) has announced results for the 13 months to 31st December 2019 (having moved its year-end from November), emphasising it “has met a significant number of important objectives that continue to build value for shareholders”. The shares have currently responded a bit lower to 62p, but the numbers are historic and look at the trading trajectory now...
Updating on OptiBiotix Health (OPTI) earlier this week we noted interest from larger partners and shorter partner discussions as sales are significantly developing. Now “a non-exclusive license agreement for its SlimBiome® trademark with Evolution_18 and related launch of fibre gummies containing OptiBiotix's SlimBiome® proprietary weight management technology”…
OptiBiotix Health (OPTI) has updated including noting first quarter of 2020 sales of £407,844 – and the shares have responded 11% higher to above 60p. Capitalising the company at around £53 million, why you may ask? Well, look at the company’s trajectory...
OptiBiotix Health (OPTI) has announced it’s “pleased to have signed an agreement… to commercialise our award-winning weight management technology in Taiwan”…
OptiBiotix Health (OPTI) has announced “a non-exclusive license agreement for its SlimBiome® trademark with Smart For Life, Inc. and related launch of cookies containing OptiBiotix's SlimBiome® proprietary weight management technology in the USA and Canada”...
Of course, those who know best will insist that this in no way validates the IP of Optibiotix (OPTI) and is a small deal which will not generate any license (and thus almost all margin with no working capital needed) profits at all. Whatever… So why has it not been announced?
A “Placing and Related Party Transaction” announcement from OptiBiotix Health (OPTI)… but we previously stated confidence of the company now moving to profitability, so are we wrong? No! In fact we are now far more bullish than ever before following a chat with boss Steve O'Hara earlier.
Last week we noted a “key” SlimBiome contract manufacturing agreement for OptiBiotix Health (OPTI)... now it “builds on” this such agreement for meal replacement shakes designed specifically to support the international expansion of its own label GoFigure® consumer weight management brand…
OptiBiotix Health (OPTI) has followed an “Exclusive licence agreement for OptiBiome®” with a contract manufacturing agreement for SlimBiome® with Fipros A/S, emphasising “the agreement is key”…
A “Change of accounting year end” announcement from OptiBiotix Health (OPTI). But isn’t that a move of fraudsters or incompetents? Not in this case…
The prices of all AIM stocks are now essentially a binary bet. They are either 100% overvalued as they will go bust or, having collapsed, are fundamentally incredibly cheap as they are not going bust whatever the share price says. Optibiotix (OPTI) is very much in the latter category. I accept folks are panicking generally or they are facing margin calls elsewhere and have to sell shares to meet them. That however is not what will drive the share price in the long run...
I have communicated with Steve O Hara. The share price of Optibiotix (OPTI) is 34p and that is freaking some folks out. The share price does not reflect what is going on. I think a formal trading statement would be useful.
OptiBiotix Health (OPTI) has updated on a number of developments CEO Steve O'Hara emphasises “support the commercialisation of its ingredients and products”…
Last week we noted a licencing agreement for LPLDL, of OptiBiotix Health (OPTI), was clearly positive with the potential then significantly added to but that Uruguay itself is clearly not the largest of markets. The latter is not the case for the United States and Canada!…
Okay it is paid for Proactive so this is not exactly Jeremy Paxman. There are no hard numbers on the big deals and that is no shock, we will have to wait for a formal half year trading statement for that ( or maybe sooner) but this is a confident showing. My numbers are HERE and the STRONG BUY stance is unchanged.
OptiBiotix Health (OPTI) has announced “a significant milestone” in extension of the use of its LPLDL probiotic strain into functional foods and its presence into South America. So what you say?...
Tom Winnifrith writes: Two days ago on this very website I gave four reasons why I have never been so bullish about Optiubiotix (OPTI) with the shares then at a 60p offer. Now the offer is 67p and the shares are still a massive buy at up to 80p with a target to top slice at 125p achievable within months.
I am now a customer as well as a shareholder having ordered two boxes of Slimbiome to help me shift, ahem, a few pounds. I shall report back on my progress. But you want to gain pounds don’t you? Well at a 60p offer, the way to do that is to buy more Optibiotix (OPTI) shares. I have as I have never been more confident about the company and its prospects. Let me explain why with reference to the four bits of news out this week...
The photos below show the two boxes of Slimbiome that arrived today at the Welsh Hovel and also one of the sachets, 21 of which sit in each box. I have used a standard loo roll in the pictures to give you an indication of size.
My training for the Woodlarks 34 mile walk is going okay. This weekend I will do eight miles up and down Moel Famau twice. Come on: start sponsoring me please HERE. But, as Brokerman Dan kindly points out, the walk would be easier for me if I was not carrying two or three stone of surplus fat along with me. He is, I fear, for once, correct. So …
If a trading statement needs explaining then it is badly written. Yet again Optibiotix (OPTI) stands accused of that. I really think the company should fire its PR PDQ. Frankly I could, and would, do a better job. As a result of a badly written release, folks are accusing boss Steve O’Hara of lying. He has not. Amid the confusion the shares have slipped to 50-52p. I have taken the chance to buy some more...
OptiBiotix Health (OPTI) has announced a first agreement with a major retailer for its SlimBiome® functional ingredient with a product range to be initially sold in the UK, Republic of Ireland, Netherlands, Belgium and Sweden by health food chain Holland & Barrett…
The screenshot below looks to be self explanatory. 715 UK stores. Ching. Ching. As I noted in bearcasts for most of the pre-Christmas week, Optibiotox (OPTI) shares are a strong buy. Might the company possibly RNS this?
Don't get me wrong, what Steve O' Hara said in an interview with Proactive today is great news for Optibiotix (OPTI), truly great news which makes the shares a compelling buy, but surely this is the stuff for an RNS? Surely it is price sensitive?
OptiBiotix Health (OPTI) is “very pleased to have been granted a medical device status and a CE mark for the second time over a 12-month period”...
Do not get me wrong. I am a big fan of Steve O’Hara. I think he is doing a cracking job at Optibiotix (OPTI) where – as a loyal and very material (for me) shareholder – I expect to see the shares more than double from 62p within the next year. However, I’d be a hypocrite if I did not hold O’Hara to the same standards as obvious scallywags like Neill Ricketts of Versarien (VRS) when it came to the disclosure of material information.
It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?...
OptiBiotix Health (OPTI) has updated investors with news including “completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LPLDL®. Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement”…
A “GoFigure agreement for Southern Africa” announcement from OptiBiotix Health(OPTI) Does this matter? Yes it all helps.
Goetz is the company's retained broker so is biased but the 55 page note below which came out today is detailed. I am a big shareholder and regard the target as, of anything, cautious given that the chairman bought shares less than a year ago at 97p. Judge for yourself...
Shares in Optibiotix (OPTI) have fallen by more than a quarter on the back on results for the six months to May 31 which are, let us not kid ourselves, really not very impressive indeed. The bears are cock-a-hoop but now talking errant nonsense. We bulls look a bit daft. As a shareholder I feel a bit sore but, having chatted to CEO Steve O’Hara at length, I retain a stance of strong buy. I see one director, Fred Narbel, has bought 17,000 shares at 50p and I expect more, larger scale, boardroom buying to follow. And this is why...
OptiBiotix Health (OPTI) is pleased to announce an exclusive manufacturing, supply and distribution agreement for its SlimBiome weight management technology in Australia and New Zealand…
Optibiotix (OPTI) shares now trade at 72p to buy after the announcement of a new deal with a company called BioEnergiser Ltd for the online distribution of SlimBiome Medical in the UK. SlimBiome Medical is a CE-marked medical device which independent clinical studies show reduces hunger, cravings for sweet and savoury foods, and fat intake. Steve O’Hara tells me this is not because Optibiotix's own online sales are slowing. Far from it. But this is just another channel to market...
An update from OptiBiotix Health (OPTI); “Scientific and commercial update”...
OptiBiotix (OPTI) has announced another license agreement to we loyal shareholders. This one is for the use of its ProBiotix’s LPLDL ingredient in cardiovascular food supplements in Japan and is set to mean a first LPLDL finished product placement on the Japanese market…
I have known that this move was in the offing for a couple of months. Quite simply the official broker to Optibiotix (OPTI), that is to say finnCap, is useless. But an AIM company needs a retained broker so it stays in place. However it is not publishing research nor is it putting forecasts into the market nor is it getting secondary buying of the stock by institutional investors. Finncap is FinnCrap...
Optibiotix (OPTI) has announced what could be its biggest supply and manufacturing deal to date and it could be generating revenues within a couple of months. This is big, very big and at 80p offer the shares are a strong buy...
More positive news from OptiBiotix Health (OPTI)?... The company has announced an exclusive license agreement for the commercialisation of, currently fully-owned subsidiary, ProBiotix's cholesterol management products CholBiome and CholBiomex3 in Vietnam…
More positive news for us loyal OptiBiotix Health (OPTI) shareholders, with an announcement of “Appointment of CEO of ProBiotix Health”…
The shares are off a tad thanks to another piss poor hatchet piece on Stockopedia, which I take apart HERE. There is actually some good news from Optibiotix (OPTI)...
Last week it was a Thai deal from OptiBiotix Health (OPTI), now there’s another for the European market...
Steve O’ Hara says he is looking to do two new distribution deals a month and so here is the first for May. Optibiotix (OPTI) has announced that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Instituto Español de Nutrición Personalizada, S.A. for the use of Lactobacillus plantarum (LPLDL) in personalised food supplements in Spain...
The shares are down on the day by a couple of pence at 72p-75p. The press release was long, verbose and not well crafted. As a loyal shareholder, I found a long chat with boss Steve O’Hara far more constructive. Optibiotix (OPTI) has never been in a better place and thus its shares are very cheap and a strong buy...
Optibiotix (OPTI) has announced the launch of SlimBiome® Medical in the UK – as of 29 April. All; well and good and I remain an enthusiast for the shares - they are cheap. But there is another matter which is not so impressive in a word where transparency is now universally viewed as critical.
It is another piece in the jigsaw and it could turn out to be quite a large one. Optibiotix (OPTI) has announced that it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its weight management product, SlimBiome to be manufactured in India. The approval was gained by Optibiotix's manufacturing partner, Zeon Life Sciences, for both SlimBiome and SlimBiome-containing products...
Another day, another deal. Is this No. 30 or 31, I rather lose count. But if you watched the interview with Steve O’Hara the other day, HERE, you will know that the majority of those already signed are now generating revenues and the curve in nearly all of those is sharply upwards. Optibiotix (OPTI) is profitable and hugely operationally geared...
It is a Proactive interview so the questions are not exactly taxing. But the ansswers given by Steve O'Hara of Optibiotix (OPTI) are illuminating. "The majority" of partners are now generating revenues. This company has signed almost 30 deals. That tells me that the massive ramp up in sales in H2 of last year will continue and indeed accelerate in H1 this year and beyond so full steam ahead. I reckon the shares are a buy at the current 84p and at up to 90p and see the shares motoring ahead to 125p+ in short order. Note what O'Hara says about the pipeline of announcements.
My attention is drawn to a press release issued by this wretched Government which should, I believe, force Optibiotix (OPTI) to make a statement and make even the most cynical of bears wake up. It reads:
The market does not seem to have picked up on the significance of the most recent news from Optibiotix (OPTI). It will.
These days Optibiotix (OPTI) is on the cusp of being or already profitable and as such what excites us are rapidly growing revenues and new sales and marketing agreements. We will not have to wait long at all for more news on both those fronts. But behind this great company is the IP, the science.
Thirsty Paul Scott was so flamed by some of his readers for his hatchet job on Optibiotix (OPTI) , littered, as it was, with false statements that he announced he would not be penning a column on Friday as he was, alongside thousands of school kids worried about global warming, going on strike. The difference between those withdrawing their labour on Friday is that the kids will, one day, grow up and most of the teenagers already produce work that is far less error strewn than that of the Thirsty one.
Both bulls and bears appear to be taking something from the latest trading statement from Optibiotix (OPTI) – the bears are wrong and what we learned is great news for we shareholders. I have chatted to Steve O’Hara at length and, as a result, I more bullish than I have been in a good while...
Another day and another hugely positive announcement from Optibiotix (OPTI) to delight we loyal shareholders. This news is from Japan.
Another week and another deal is announced by OptiBiotix Health plc (OPTI). This is a three year supply agreement with Biolat JSC covering the supply of its cholesterol and blood pressure reducing LPLDL® strain in Estonia, Latvia and Lithuania. It seems that in the Baltic states they are more likely to die of heart disease than anyone else on this planet so it is not a bad target market.
The latest deal from Optibiotix (OPTI) is a three year distribution agreement with a company called SilvEXPO Ltd to distribute and commercialise OptiBiotix's own label CholBiome products containing its cholesterol and blood pressure reducing LPLDL strain in Russia and Kazakhstan...
OptiBiotix Health (OPTI) has announced that it has entered into an exclusive manufacturing and supply agreement with Zeon Lifesciences. The agreement grants Zeon an exclusive license to manufacture and supply OptiBiotix's SlimBiome weight management technology in India, in return for 50% of the profit...
The evolution and growth of Optibiotix (OPTI) continues with a change of personnel which we should welcome...
OptiBiotix Health (OPTI) has announced that its formerly wholly owned subsidiary ProBiotix Health Limited has raised £1.025 million of capital through the issue of convertible loan notes. So what you say?
Optibiotix (OPTI) boss Steve O’Hara has dusted down his Adam Reynolds keyboard for another RNS which the market seems, unwisely to ignore. But we, the faithful shareholders, will be rewarded for our patience with something far more stirring and we shouldn’t be waiting very long at all...
On Tuesday we learned how Optibiotix (OPTI) had secured medical device approval for Slimbiome and a CE Mark and that it had been working on this for two and a half years. We suggested that it would thus hit the ground running and so it was perfectly plausible that it could be delivering annualised profits of £7 million from this one product within two years. On Thursday we saw evidence of how well prepared it is for a rapid rollout.
Okay, I know that an interview with Proactive Investor is not exactly taxing, the questions make those posed by the Sith Lord Zak Mir look like the Spanish Inquisition in full flow. But Optibiotix (OPTI) has more great news today and Steve O' Hara rams that home in the video below. The shares are 96p and I am certainly not selling any at anywhere near this price - they are going a lot higher.
“This is the second most important announcement we’ve made since we listed.” So said Optibiotix (OPTI) boss Steve O’Hara as we chatted this morning. The news is massive. Having worked on gaining medical device status and a CE Mark for the weight loss product Slimbiome for two and a half years, permission has finally been granted...
Shares in Optibiotix (OPTI) have not been immune to the general market sell off and trade at 64p-66p despite some more positive news. The frustration is that it has been announced with a release typed on the Adam Reynolds keyboard, the one with no numbers on it. But fear not bigger deals with real numbers will follow shortly...
Having reached circa 130p in August, shares in OptiBiotix Health (OPTI) have slid to 78p-81p. This is despite a pipeline of seemingly very significant deals likely to be converted and as such…
Having top sliced our holdings in Optibiotix (OPTI) a few weeks ago I see the shares are back at 94p today despite it having served up cracking news last week. I am asked if I am panicked? Not at all. I fully expect the shares to bounce sharply on more good news. Are we buying more? No I stated clearly, I wanted to build up our cash reserves as I am worried about the market. That has not changed. Yesterday CEO Steve O'Hara did an interview with Proactive and if you are worried watch it, below, and you should be greatly reassured.
This was our August share tip of the month which came out last week: Having advised you to bank some gains on Optibiotix (OPTI) a couple of weeks ago at 131p we see that the shares are now just under 100p following results yesterday. We were sorely tempted to make this our tip of the month again as we are sure that there will be a stack of news in the coming weeks on some really big name deals ( with numbers!) and that we could have advised banking a quick 30% gain by mid October. You can hear Tom Winnifrith’s thoughts on Optibiotix in his Thursday bearcast HERE But that trade would have been a bit spivvy don’t you think? So instead…
I do not apologise for a second for advising folks to top slice Optibiotix (OPTI) at 131p but today the company has served up news which shows why it was right to hang onto at least part of your holding ( and we have held onto 6/7 of ours). Today’s release is big and does not use the Adam Reynolds keyboard – there are real numbers and big numbers.
What looks like wallpaper in Mr Rehne's spare room really is ghastly and I am not sure what a director of Optibiotix (OPTI) is doing recording a webcast with investment hookers Proactive, a week or so before results day, but whatever, what do I know. Per seems in upbeat mood. For the record, having followed our own advice and top slice ( selling c 1/6) of our holding at 125p, we are not selling any more at the current 108p-111p.
Optibiotix (OPTI) has announced that subject to regulatory clearance, a formality, it will appoint Sean Christie as an additional Non-Executive Director.
For eons Cynical Bear has made one of his seven things that will never happen series, that Optibiotix (OPTI) shares would not reach 100p. As you may have twigged, they have reached and now breached, closing last night at 124p. And with a very pregnant deal pipeline so a stack of RNS's on the way, we who ignored the old Bear are feeling happy. I teased him that by way of apology he should send a bottle of ouzo to Sheriff of AIM Towers. He is a good man old Cynical Bear. Late last night, guess what arrived...
Three weeks ago Optibiotix (OPTI) Chairman Neil Davidson bought £150,000 worth of shares in the company at 71p and said in a TV interview that he would buy more when the time was right. Heck, he has now averaged up!
As Cornelius Nepos said: “After the darkness comes the light” and having been in despair last month writing June’s update, I am back to my bouncy best as Optibiotix (OPTI) has become the second Mythical Wonder to become real and in some style…..although I hope it now performs better than the first!
Amazed to find that one of her share tips had actually gone up, Jo Hart of the Midas column In the mail on Sunday advised the poor saps who follow her to top slice or sell Optibiotix (OPTI) on Sunday. Just as a buy note from Ms Hart is seen by most folks as a sure sign that a PR puff campaign is underway and that you should sell at once, the Midas sell stance seems to have pushed the shares ever higher as the chart below demonstrates. Yes £1 hit again, another case of ouzo Cynical Bear needs to send me. I discussed why I’d not be selling at this price as I expect fireworks soon HERE. Meanwhile…
First there was his flip flop On Sosandar (SOS) when he ‘fessed that his bearishness was an error. Now Cynical Bear’s much repeated claim in his seven things that won’t happen series, that Optibiotix (OPTI) would not hit 100p is in tatters too as the shares have this morning touched that level. Time for another volte face? And more importantly…
Okay the video is from blowjob TV that is to say Proactive from yesterday and thus the interviewer makes Zak Mir look like Jeremy Paxman. But, remembering that chairman Davidson has a reputation to lose, take note of what he implies about buying even more shares and also about deals not yet announced. His quiet confidence is clear and that is why even at 86p-88p you would be certifiable if you sold. We certainly will not be at anywhere near this level.
It is not as if Optibiotix (OPTI) management do not put their money where their mouth is. Just a few days ago chairman Neil Davidson splashed out £150,000 buying shares at 71p. Now we have news of an option package for three senior staffers including Davidson. No options….one way bet… nooooooooooooo you scream. No. Read the RNS.
Okay, the Optibiotix (OPTI) chairman does not get everything right. He is, after all shacked up with mad remoaning Tory MP Anna Soubry. But no-one is perfect. What we can say is that Neil Davidson has had a glittering business career so has a reputation to lose. His salary as Non Exec chairman will not make much difference to his net wealth but buying shares could.
Neither myself or the audience gave Steve O'Hara of Optibiotix (OPTI) an easy ride at Monday's UK Investor event in the City. But he presented well and I note that the chairman has today announced the purchase of £150,000 of shares at 71p. Watch Steve closely and you will see why the chairman is buying and why the shares - which are our largest holding but one we have added to in the past couple of months - are so cheap.
Below are a few photos of last night's UK Investor City evening with myself, Nigel Wray, Steve O'Hara of Optibiotix (OPTI) and Cambridge Cognition (COG).This is what you missed if you were not one of the 100 attendees. The next event is in September - to make sure you can priority book, you might join the mailing list for the events HERE
Optibiotix (OPTI) has announced what is its 14th (or is it 15th) big commercial partnership. But how big? Thanks to a Nomad who needs shooting it has taken us 36 hours to find out. So here goes.
Maybe folks are getting immune about Optibiotix (OPTI) announcing yet another manufacturing and supply agreement. But even if, like this one, it is relatively small it all adds to the bottom line improvement. The latest one is with John Morley Foods, a 75 year old company operating in Cheshire with annual sales (2016) of £31 million, making six figure profits and with a growing cash pile.
Optibiotix (OPTI) has announced that a global dairy company with an annual turnover of more than $10 billion has signed a deal to evaluate its SweetBiotix calorie free sweet fibres.
After the results last week the knockers said that Optibiotix (OPTI) would place as it was running out of cash. They were half right, but half very wrong. So before they gloat.
The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been on April 21st, here’s a first performance update...
This may well be the biggest supply deal yet announced by Optibiotix (OPTI) but Mr Market seems unmoved. The shares are 73p-75p and are a STRONG BUY. Let us explain.
It is not exactly earth shattering but Optibiotix (OPTI) says that it will be showcasing "an extended range of products and presenting new research data on its LPLDL® and SlimBiome® products at the Vitafoods European tradeshow in Geneva from the 15-17 May 2018."
I chatted to Steve before the show and at it. This is my biggest single holding, I bought more after the show and at a 71p offer shares in Optibiotix (OPTI) are IMHO still very cheap. I really do expect them to be at 120p+ during the coming months as it unveils a string of new sales agreements. Here is Steve in action...
Chaired by Adam Reynolds this session boated the CEOS of Immupharma, Optibiotix, soon to IPO Phynova and ValiRx. Enjoy.
What an odd situation. Optibiotix (OPTI) has been forced to comment on an article in Business Insider relating to Seed Health which, the article states, has purchased LP-LDL for use in its multi-strain product which is intended for launch in the USA in May 2018. Seed Health is hot, being backed not only by Cameron Diaz but by legendary investor Peter Thiel.
OptiBiotix Health (OPTI) has added to recent newsflow aplenty with a distribution agreement for its SlimBiome weight management technology in the UK…
Recent newsflow aplenty from OptiBiotix Health (OPTI) – including ‘Appointment of Head of Online Sales and Marketing’, ‘ CholBiome exclusive distribution agreement’ and ‘New patent filings for SweetBiotix’…
There appears to be a sustained seller of Optibiotix (OPTI). I believe he is close to completing his exit but the truth is that I don't know. Short term that has depressed the shares to 55p-57p. Thanks for the opportunity pal.
Heck, even semi-pro Adam Reynolds baiter Cynical Bear seems to be warming to Optibiotix (OPTI) as you can see HERE. And there are fundamental reasons for this. We noted last week:
You know that I view soft soap paid for interviews with folks like Proactive in a deeply negative way. But Steve O' Hara of Optibiotix (OPTI) comes, I believe, across well and explains the import of recent announcements. In this interview O Hara gives the sort of hard numbers I have used in my writings on this stock. Paul Scott shows an extremer double standard in describing this as "nudge, nudge wink, wink" - I just called it talking to a company which is what anyone sensible would do. I explain why Scott is talking cock and applying double standards HERE. As for Optibiotix, do your maths listen to the whbole interview ( the last 30 seconds are very interesting), the shares are incredibly cheap at 62p offer and will go to well over 100p this year if half of what O'Hara says in this interview comes good. BUY.
Optibiotix (OPTI) has announced that it has signed a production and commercialisation agreement with Fine Foods & Pharmaceuticals N.T.M. S.p.A. The agreement grants Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties.
Okay this is a Proactive interview where the sycophantic cocksuckers ask only soft questions. But the statements Steve O'Hara of Optibiotix (OPTI) makes on the value of deals signed ( 4 minutes in) and the pipeline explain why I am so bullish. And perhaps why the chairman has just bought £100,000 worth of shares, something announced this afternoon. At 63p offer the shares are a storming buy ahead of a stream of big contract wins which will, finally, push the stock to 100p and beyond, IMHO.
OptiBiotix Health (OPTI) has announced what it terms "successful" human taste studies in its SweetBiotix product development programmes. Okay this is all good, but this is not the big banana.
We are, again, asked to explain the announcement made by Optibiotix (OPTI) about a forthcoming GM. Okay here goes!
To date Optibiotix (OPTI) has signed six deals each worth £250,000-500,000 per annum in gross revenues to it. We do not know when exactly they start to kick in, although some have done so already. But we know that there is enough there to ensure that PLC costs of c£1 million a year are well covered in calendar 2018 and so the company will record a profit. Now comes news of the seventh - and biggest - deal to date.
Adam Reynolds is a man to do an RTO, a man to chair a small company. There comes a time - you hope - when the company grows to a bigger level and you need a bigger company man as Chairman. That time has come at Optibiotix (OPTI).
Oh well, apparently he is a very astute businessman. But as for his other half... As a diehard Brexiteer I have to question at least one aspect of Neil Davidson's judgement, his better ( well sort of) half in action below - the bit where Nigel Farage duffs her up on ship building is especially good. But I still think the shares are very cheap! None the less I must now acceptr that the chair of our biggest single investment is sleeping with the enemy.
OptiBiotix (OPTI) has announced that it will be seeking shareholder approval to undertake a share capital re-organisation to allow the company to make future dividend payments. This is an accountancy matter - you can't pay dividends if you have retained losses. It is a clear statement of intent.
There is no news of new distribution or partnership deals in this release but fear not they will come soon. Very soon. But none the less, the latest update from Optibiotix (OPTI) on progress at Slimbiome is very positive indeed and, yes, Tata, is mentioned.
A big deal with a real name and a serious player which will lead to material profits for Optibiotix (OPTI). What more could we lucky shareholders want? These deals are racking up and will clearly leave the company reporting profits in 2019 and very big profits the year after. That is not discounted in the share price, currently 74p to buy.
Okay we have been bullish on this one since the shares were 8p – when we bought our shares – but it has not raced ahead in recent months as much as we would have expected. The market simply has not appreciated the importance of recently announced deals and also the business model. Once it does, and that will come as other big deals are announced, the shares will move ahead very sharply indeed.
This is not going to get the shares soaring, but it is further affirmation of the technology that Optibiotix (OPTI) owns and which it is showing an increasing ability to monitise.
A previous announcement from OptiBiotix (OPTI) we lambasted as non-news, but noted we expected a rally from the then 65p-66.5p on real news for which we will not be waiting long. The company is today “pleased to announce” a three year supply agreement with Spain-headquartered pharmaceutical group Galenicum “to commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL”.
This is non news and Optibiotix (OPTI) should fire whatever poltroons handle its PR for releasing it. Announcing guffe creates the impression that a company has nothing of substance to announce which is not the case.We, for instance, expect news of a massive Slimbiome Tata deal with hard numbers very soon.
The last of David Evans's shares in Optibiotix (OPTI) have been placed out today at 60p according to a reliable source.
Ahead of a presentation in London, Optibiotix (OPTI) issued what you might term a "cleansing statement" allowing boss Steve O'Hara to talk freely. And the news is all good. Let's start with Slimbiome.
I gather that there are still about a dozen seats going for tomorrow evening's presentation evening hosted by Turner Pope. Natch the main attraction is the free food and drink on ffer in Mayfair. But, more seriously, there are three companies presenting and taking questions.
We have had a few emails about the share sale announced by former Optibiotix (OPTI) director David Evans. Panic not. The shares are back at 69.5p mid on the news: treat that as a buying opportunity.
Oh Ye of little faith!. There was big news on Tuesday for Optibiotix (OPTI). This was ONE of the big deals we were waiting for. There are more to follow but this should send critics of Optibiotix scuttling for cover as India's Tata is a giant. It has 660,000 employees and annual sales of $103.51 billion! Those who doubted us as we bought our first shares for two years HERE - at sub 55p a few weeks ago you can apologise. now. Go form an orderly queue. The shares are now 75p-77.5p and they are GOING MUCH HIGHER & SOON!
There were no great surprises in the results for the six months to May 31 from Optibiotix (OPTI). Maybe that is why, after a decent bounce, they are off a tad at 67p-70p. But those taking profits are making a mistake for there will be fireworks soon and that will see the shares soar.
Another day sees another piece of good news from Optibiotix (OPTI) with the shares again ticking higher, to 72p, on the back of it. There is a lot more news in the pipeline, a lot more blue days to come in the next few weeks and months. So where are we now? Let's start by dispelling a myth or two.
Optibiotix (OPTI) has announced that it has extended the Europe wide supply agreement announced with Sacco in March to cover the USA and Rest of the World. The new deal grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in the US and ROW, in return for 50% of the profit, with a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting.
Thanks for all the emails on Optibiotix (OPTI). We understand seeing the shares slide back to 53p odd is alarming. To one or two of you, there is no need for such language! To the rest of you here goes.
Optibiotix (OPTI) has announced that its German partner HLH has achieved product registration of capsules containing the Optibiotix product LPDL and started commercial sales to drug stores on July 24.
OptiBiotix (OPTI) has announced another sales deal. Like others it is small to start with but will build up and this grows more and more reminiscent of the early days of ARM. Check out the Steve O'Hara quote at the end of the release.
Optibiotix (OPTI) has announced the success of human taste studies in its SweetBiotix® product development programme. The programme has been designed to develop sweet natural healthy fibres, called SweetBiotix®, which are not digested in the human gut, and hence calorie free.
Okay I do not own these shares personally. I case anyone is thinking of going for me in a libel case I own nothing but FIML, owned by my family trusts, has built from scratch a fairly sizeable portfolio of 18 stocks. For what it is worth here they are in descending order of current value.
On 25 April this year Optibiotix (OPTI) announced it had delivered a small sale of 100,000 units of its LPDL capsule to Germany's HLH BioPharma Vertriebs GmbH. That must have gone well as we are today told that Optibiotix has signed a three year deal that grants HLH a non-exclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LPLDL® strain.
OptiBiotix Health (OPTI) has announced what it terms the "successful" launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry. Yadda, yadda, yadda. Companies always say launches are successful. More jam tomorrow. So what. Etc. But no read on... We have underlined a few key words for you.
Shares in Optibiotix (OPTI) hit 60.5p mid at one point Wednesday but closed at 61p-63p. Having retipped this as a buy in the low seventies and at up to 80p we have received a number of emails saying "should we sell?" Some were citing savants on the LSE Bulletin Board who make dire predictions and others were asking what is wrong?
Morning Tom, people on the BB speculating you have sold your OPTI holding, can you confirm please?Thank you. That was one of the emails that I received this morning. The short answer is "its bollocks" but perhaps this merits a longer answer.
The A-Grade A'holes at Walbrook PR who charge Optibiotix (OPTI) thousands of quid a month for "news management" probably thought putting out two announcements on one day was part of a clever strategy. Whatever. If Optibiotix wants to save a few quid we have a suggestion....
In this video from the storming success that was the 2017 UK Investor Show, in the 'Dragon's Den' companies have a 60 second pitch to Gary Newman, Tom Winnifrith and Steve Moore for three £1,000 investments. This third round features Optibiotix (OPTI), Metal Tiger (MTR), Saffron Energy (SRON), Collagen Solutions (COS) and Wishbone Gold (WSBN).
OptiBiotix (OPTI) skin health-focused subsidiary, SkinBioTherapeutics, has successfully listed its shares on AIM. Good news as OptiBiotix still has a near 42% stake…
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.
If Optibiotix (OPTI) said that 2 +2 =4 then some folks would start banging on about how that means it cant equal three. There is no pleasing them. Thus after the cracking deal with Sacco announced earlier this week all some folks wanted to talk about was P&G.
Oh ye of little faith! Ye who panicked that Optibiotix (OPTI) has not publicly announced that the big name party in the last deal was Tata. Fear not it will and there will be exciting news on that soon. Ye who thought there were no more deals. You were wrong and that is why we have been urging you to buy the shares at up to 80p again and again. The shares are now 71p-74p.
An early contender for the most idiotic email of the day has just arrived. It compared an RNS out this morning from Optibiotix (OPTI) about launching new products and pushing existing ones to the sort of RNS that the recently suspended fraud Cloudtag (CTAG) used to issue. It is hard to know what to say in the face of such stupidity. There is a clear difference.
Critics of Obtibiotix (OPTI) reckon that it is all jam tomorrow and it needs to announce big name deals which see real rollout of its products and commercialisation. Well how would a deal with Boots for its Slimbiome weight-loss drinks and snack bars do for starters?
Optibiotix (OPTI) held an EGM of warrant holders earlier this week to vote on extending the date at which we must exercise out to 2022 from er...next week. There are really very few warrant holders left.
After languishing unloved for a while in the low sixties, shares in Optibiotix (OPTI) are really steaming ahead and are now 78p to buy. We hope you bought in the low sixties as we repeatedly urged. If not it is not too late. The shares are a buy at up to 80p and I expect to be advising you to sell at WELL OVER 100p by Easter. So what has happened?
There are some announcements that an AIM listed company has to make as they are material but in terms of excitement we are talking paint dry. So you just clear the decks and announce them and when all the news is out you - hopefully - have something to announce which will get folks interested. And so it is with Optibiotix (OPTI).
We cannot hide our disappointment that we go into Christmas with shares in Optibiotix (OPTI) trading at just 61-63p. They really should be far higher and we do expect an exciting re-rate in Q1 2017. We had expected it earlier but were wrong. We won't be this time!
On 29 November Optibiotix (OPTI) stated: "OptiBiotix reports that it has reached late stage commercial discussions with six commercial partners across its technology and product platforms.". The knockers said "jam tomorrow won't happen". This week the first of the six deals was announced and it is massive. More will follow as Adam Reynolds made clear yesterday exclusively HERE. The news is:
Earlier Adam and I chatted about Concepta (CPT). In this podcast we cover Optibiotix (OPTI) and Premaitha (NIPT).
We Optibiotix (OPTI) shareholders have been feeling a bit under the cosh of late as the shares weakened on a lack of news. It was just ennui among those of an impatient disposition but still it was annoying. This week's trading statement should reassure the doubters.
OptiBiotix Health (OPTI) has served up an update which is good but not the sort of fireworks investors were hoping for. As a result the shares closed at 61.5p-63p on the day which is, to say the least, disappointing. They are now 63p-66p which is better but still both disappointing and far too low.
Optibiotix (OPTI) has announced the appointment of Martin Hunt as Chairman and Director of its majority owned subsidiary SkinBiotix Limited. Why does this matter? Because this unit will be spun off with a separate AIM listing well before Christmas. This is one of the last box ticking to do before formal confirmation of the process.
We have been asked a few questions about Optibiotix (OPTI), none wildly important and so let's wrap them up into one article, in Q&A format.
The good news is that a 1.5 million share overhang in Optibiotix (OPTI) has now been cleared. So the shares should soar on good news. The bad news is that we have to wait a bit longer for that good news... Instead we get an RNS that was never going to set the share price on fire. Optibiotix has announced the results of a survey of customers of its GoFigure slimming shakes and bars. 30 lard buckets took part in the survey.
Results from the half calendar year from Optibiotix (OPTI) were very pleasing indeed but not orgasmic and that is why the shares are a tad weaker at 69p-72p. They are cheap but punters need to see more. They will not have to wait too long.
I have received a number of emails and texts asking if I am worried that shares in Optibiotix (OPTI) are 67-69p having fallen back of late. No I am not but to stem the flow of questions...
Optibiotix (OPTI) has announced that its GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15 billion turnover in 2015) American supermarket chain exclusively featuring healthy foods. That sounds big but in fact it means being on the shelves in just eight stores although Optibiotix says there are " opportunities for further expansion".
Okay, okay we did notice! In response to several reader emails we had seen that Optibiotix (OPTI) had yesterday appointed Luis Gosalbez as Director of Business Development, effective immediately. we are sure that Luis is a charming chappie and his CV looks awesome but it is not even a board appointment so its no great fuss. However....
Good news. This is the sort of thing investors have been wanting Optibiotix (OPTI) to announce and it is delivering. The company says that the trial launch of its Slimbiome® ingredients in a range of meal replacement shakes and natural snack bars went well. In independent tests the ingredients of bars and drinks including Slimbiome showed fatties cutting calorie intakes by 20% or more and suffering fewer cravings.
As house broker to Optibiotix (OPTI), Hybridan is paid to be a fan and on that basis you should really take its bullishness for granted. But a note published a few days ago, before today's cracking news, explains the bull case and since we own shed loads of these shares why not give this most excellent report a wider airing. If the target was 106p pre today's good news surely it would be higher now as analyst Derren Nathan ( not a total poltroon) could cut the risk weighting on one product?
This is more good news from Optibiotix (OPTI) but it is not the dramatic news that will see the shares soaring. The company says that it has announced that it has filed a new patent to protect the combination of OptiBiotix's Lactobacillus plantarum strain along with other ingredients identified by scientific key opinion leaders which, it states, act synergistically to reduce cardiovascular risk factors.
Optibiotix (OPTI) has this week served up news which should help make we shareholders richer in the medium term. But it is NOT the news punters wanted and the shares trade at 79p-80p.
Following Sunday's exclusive news here about an Optibiotix product to help us lose weight being trialled out on Amazon I am asked if that means that the deal with Slimfast, the multi billion dollar slimming drinks company is off? No. It is not. I emailed CEO Steve O'Hara who said:
Certain folks have noticed that a product range called Slimbione has gone on sale and asked if it is anything to do with Optibiotix (OPTI). Here is what CEO Steve O'Hara told us exclusively:
Shares in Optibiotix (OPTI) have drifted on a lack of newsflow back to 76p to buy. Well they had when this article came out yesterday. After its appearance they jumped to 79-92p. That is the advantage paying subscribers get. If you can buy at up to 80p next week do so. We really do see 100p+ happening very soon. Why: we have just swapped emails with the company and what CEO Stephen O'Hara says in response to the question "all a bit quiet is all on track?" seems very positive indeed. O' Hara says:
OptiBiotix Health (OPTI) has announced that it has filed a new patent to protect advances made in its skin division in identifying microbial proteins which have the potential to prevent Health Care Acquired Infections (HCAI) caused by antimicrobial resistant (AMR) superbugs such as MRSA. The company says HCAIs lead to higher morbidity and mortality, and cost the NHS an estimated £1 billion per year. This represents a global market opportunity of $82 billion.
At UK Investor Show on five occasions CEOs appeared on the main stage to pitch to the Dragons (myself, Gary Newman, Steve Moore and Brian Kinane). We invested £15,000 after all these sessions. Enjoy session 5.
In this session Adam Reynolds and I discussed how to value shells and when to invest, issues of management, AIM investment companies and of course Optibiotix (OPTI), New World Oil & Gas (NEW), Frontier (FRI), and Premaitha (NIPT). Enjoy.
We bought this stock and tipped it at 8p. The shares are now c80p and we still hold more than half our holding and won't be selling them for anything less than 100p. we are bullish and after this presentation by Optibiotix (OPTI) boss Steve O'Hara I hope you can see why. Enjoy.
Optibiotix (OPTI) will be presenting on both the main stage and in a breakout room at UK Investor today!. The mood in the camp is incredibly upbeat and we hope you grab a chance to chat to CEO O'Hara to see why.
We own the shares so we are totally biased and a reader who owns the shares is also biased too but asked us to get our mitts on a recent report from Galvan on Optibiotix (OPTI) and publish it. So here you are.
Hybridan is house broker to Optibiotix (OPTI) and so although I agree with its conclusion this note is clearly biased and feel free to ignore it completely. As for Hybridan, like most brokers. its employees should be strung up with piano wire. But for what it is worth.
A bloke in the City said that although results from Optibiotix's (OPTI) trials of its capsular supplement to reduce cholesterol looked great he was so fat that he was beyond redemption. Maybe. But for others results were startling. There is a caveat:
Shares in Optibiotix (OPTI) slipped back to 66.5p - albeit in thin volumes - two days ago as it announced news which was really not very exciting at all. The news we want we now expect very shortly after Easter. The shares are now 70p. Hang on for what comes next!
Optibiotix (OPTI) shares trade at 69p-70p having slipped on news yesterday which was "the wrong sort of good news". Fear not. The right sort is imminent. The wrong good news was that it has set up a 52% owned JV with the University of Manchester called SkinBiotix. Optibiotix says that:
We own stacks of shares in Optibiotix (OPTI) so naturally we agree with Hybridan analyst Derren Nathan that the shares are cheap at 71p. Mr Nathan published a new note late last week so you can make up your own mind. We expect big news soon and sure are not selling our shares.
Broker Hybridan has not (yet) published research on Optibiotix (OPTI) following last week's City presentation. But it has sent a private email to certain clients and, put it this way, we are not going to be selling on the basis of what follows. It strikes me that we may see some very big news soon. Hybridan director of Corporate Broking William Lynne states his key takeaways:
Optibiotix (OPTI) yesterday announced that it had raised £1 million at 78p. It saw this as a triumph in that the investor is an EIS fund which approached it. So the shares will be held for three years and not flipped.
Optibiotix (OPTI) last week announced a potentially massive deal with Slimfast. But no-one seems to have noticed as the deal anounced is with KSF Acquisition Ltd. Investors appear to be saying KSF who?
Featuring shares in Berkeley Energia (BKY), Glenwick (GWIK), MX Oil (MXO), Obtala Resources (OBT), Optibiotix (OPTI) and Rare Earth Minerals (REM) with share price targets for all six stocks.
We own these shares so feel free to ignore what we say. But for the avoidance of doubt our next top slice order is with our broker at more than 95.4p. In fact it is at more than 100p. Hybridan is house broker to Optibiotix (OPTI) so its research cannot be regarded as impartial either. It is paid by Optibiotix. But it has just published a note with a big upgrade so here you are.
Featuring shares in Castle Street Investments (CSI), Mobile Streams (MOB), Optibiotix (OPTI), Pantheon Resources (PANR) and Tern (TERN) with share price targets set for all five stocks.
Featuring shares of Independent Resources (IRG), Optibiotix (OPTI), Oxus Gold (OXS), Stratex (STI), Vast Resources (VAST), together with some share price targets.
Featuring shares in Aminex (AEX), Audioboom (BOOM, Concha (CHA), Optibiotix (OPTI), Sovereign Mines of Africa (SMA), together with some share price targets.
We own shed load of these shares and would certainly not be selling at the current 49.5p bid as we expect big news soon and so I offer no comment on this note from house broker Hybridian on Optibiotix (OPTI) out last week. So Just FYI
OptiBiotix Health (OPTI) has announced the registration of five new microbial strains under the Budapest Treaty, increasing the number of registrations to eight, to protect the “recent advances” the company notes to have made.
Optiobiotix (OPTI) last weekreleased the much awaited results of the human trials. Or rather it has not. Mr Market has not twigged this at all. The shares are a buy at 42p or below as we expect them to be heading towards 60p VERY quickly.
I’m biased as RMPC owns stacks of these shares. So please take that caveat on board but here is a pretty comprehensive note on Optibiotix (OPTI) from Investor’s Champion which – I think – explains why you should be so excited about this stock.
It is all very well to ridicule the Daily Telegraph’s top ten AIM shares to buy to dodge IHT as I did yesterday HERE but could you do any better asks a reader. Possibly not, I don’t really like the AIM Casino but I am always up for a challenge so here goes.
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at shares of Argos Resources (ARG), Optibiotix (OPTI), Zoo Digital (ZOO) and offer some share price targets.
The numbers for the six months to May 31 from Optibiotix (OPTI), the AIM listed developer of compounds to tackle obesity, high cholesterol and diabetes matter far less than the supporting text. If you can buy at 40.5p or below (the spread is now 39-40.5p) do so as we see a September whoosh for the shares.
Featuring shares in AMC Minerals (AMC), Falkland Oil & Gas (FOG), Gulf Keystone (GKP), Optibiotix (OPTI), Rockhopper Exploration (RKH), Xtract Resources (XTR) with share price targets for all
OptiBiotix Health (OPTI) has announced completion of clinical studies on its capsular food supplement to reduce cholesterol with no compliance or safety concerns raised. This is good news.
Last time we tipped these shares we made 200% plus. So far this time we are a shade down. But that presents a new buying opportunity created by general market weakness.
AIM listed Optibiotix (OPTI) has been a massive winner for us as a share tip already on HotStockRockets - we banked a 200% + gain back in March the first time we tipped the shares and we tipped them at 39p a month ago. Right now they are up a smidgeon% but we expect a big move very shortly... Let us explain
Hybridan is house broker to Optibiotix (OPTI) and so its views can be largely ignored.It is paid to be bullish. But by way of background here is its post results commentary which we happen to agree with. Busted clocks and all of that.
We have tipped Optibiotix (OPTI) before and our readers have banked big gains on it. Now the time is right for re-entry and this Adam Reynolds biotech play is one of our two tips of the month - the other can be found HERE for just a fiver. As ever, no member of our team will sell until 24 hours after a sell note has gone out on HotStockRockets.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at Camkids, China Chaintek, Optibiotix
If you want me to analyse a stock for you just drop me a line at email@example.com - I start this daily feature with a look at Optibiotix (OPTI) , Plethora (PLE) and Tungsten (TUNG).
I am asked by a couple of readers whether RMPC is buying more Optibiotix (OPTI) or selling as the shares have fallen back to 31p from c40p. As we do not follow this as an official tip I just pen a couple of thoughts.
Adam Reynolds is the shellmeister, the company rescurer (see HERE) and he gave a masterclass presentation at the UK Investor Show on how to make money from shells and how they work. Enjoy
The largest holding that Real Man has in its portfolio is Optibiotix (OPTI). At 34.5p we are, quite amazingly, looking at a 300% profit (plus warrants) on our initial investment. The size of the holding is, I admit, a trifle frightening as are the gains. But although we have advised readers to bank gains we are not doing that ourselves. Are we mad? I think not.
OptiBiotix Health (OPTI) has announced the appointment of a Commercial Director – Jim Laird – who has worked in commercial and corporate roles for some of the world's leading food companies and should enable OptiBiotix to develop a wider range of product and partnering opportunities.
Lets be upfront, RMPC owns this shares and since I often say that all brokers notes are worthless piffle I cannot make an exception here. However broker Hybridan has initiated its coverage of Optibiotix (OPTI) with a very bullish assessment indeed.
We told you on Wednesday that hot news was on the way. On Thursday OptiBiotix (OPTI) announced that it had agreed a 50/50 jv deal with Nizo – the Dutch company that tested its products in yoghurts and found them safe non taste altering.
Last week Optibiotix (OPTI) announced that it had appointed three men in white coats to its Scientific Advisory board. We are sure that Professor Patrice D Cani, Professor Jens Walter and Steven Morrison are all good chaps but it is not the sort of news that tends to get investors that excited.
As I noted in my ten macro themes for 2015 article (HERE) the analysis that Steve Moore and I serve up is bottom up – that is to say company specific – not so much macro driven. But the odd macro think session establishes useful tramlines for the investment process. My first, second and third share tips for 2015 are already live and so onto Number 4.
Shares in Optibiotix (OPTI) are now trading at 22p -22.5p – it was only a few months ago that we tipped them at a 9p offer. There is news today but the fun is only just beginning. The announcement today is not exactly concrete but shows momentum. It reads:
I tipped Optibiotix (OPTI) at 10p just three weeks ago and the shares are now 21p. Normally I’d say sell the lot and thanks for a 110% gain but on this occasion…
We tipped shares in Optiobiotix (LSE:OPTI) just a few months ago at a 9p offer. Knock me down with a feather they closed Friday at 20.75p-21.25p. But the fun is not over yet. We urged you strongly a week ago to buy at up to our limit buy price of 15p as the last chance to get in cheap. We hope that advice was taken even if you ignored the original tip.
OptiBiotix Health (OPTI) has announced positive results of trials of its anti-obesity compounds in fruit yoghurts in tests carried out by its Dutch partner Nizo. The trials showed clearly that adding the compounds did not impact on taste, texture, etc.
Today I start a collection of three biotech companies that I think have brilliant upside potential. Biotech firms can fly on bullish news on their products and these are three firms that I am banking on to do that. These could be genuine multibaggers if they meet expectations or grind lower if they do not.
Heck, I am biased, we own these shares, but I thought that the presentation by Steve O'Hara and Adam Reynolds of Optiobiotix (OPTI) at the second ShareProphets seminar was pretty compelling. I certainly view the shares as cheap on the basis of what I heard. To ensure that you get priority booking for future seminars (the next one is on 27 October ) and features myself, Amanda van Dyke of Bluebird Merchant Ventures, Rob Proctor of Audioboo and Cathal Friel of Fastnet Oil & Gas register HERE.
OptiBiotix Health (OPTI), the former Ducat Ventures, has announced it is contracting Netherlands-based Nizo Food Research BV to undertake pre-clinical claims support for three cholesterol-lowering ‘Lactobacillus’ strains that OptiBiotix has developed.
I am feeling rather virtuous today. Just a Greek salad and a coke to eat and I have already done one hour’s manual labour in the fields. I am just off for another stint now. I am pretty sure that my Body Mass Index is back in the “normal” range and as someone with diabetes – thanks to eating and drinking too much – that is good news. I’m heading the right way. But the rest of the world is not.
Search ShareProphets |
Recent Comments |